OA12929A - Pyrazole derivatives as transforming growth (TGF) inhibitors. - Google Patents
Pyrazole derivatives as transforming growth (TGF) inhibitors. Download PDFInfo
- Publication number
- OA12929A OA12929A OA1200500078A OA1200500078A OA12929A OA 12929 A OA12929 A OA 12929A OA 1200500078 A OA1200500078 A OA 1200500078A OA 1200500078 A OA1200500078 A OA 1200500078A OA 12929 A OA12929 A OA 12929A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- cio
- phenyl
- cycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41214602P | 2002-09-18 | 2002-09-18 | |
US48454303P | 2003-07-02 | 2003-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12929A true OA12929A (en) | 2006-10-13 |
Family
ID=32033585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200500078A OA12929A (en) | 2002-09-18 | 2003-09-08 | Pyrazole derivatives as transforming growth (TGF) inhibitors. |
Country Status (27)
Country | Link |
---|---|
US (4) | US6958354B2 (es) |
EP (2) | EP2165708A3 (es) |
JP (1) | JP4519657B2 (es) |
KR (1) | KR20050044807A (es) |
CN (1) | CN1681501A (es) |
AP (1) | AP2005003263A0 (es) |
AR (1) | AR041272A1 (es) |
AT (1) | ATE450258T1 (es) |
AU (1) | AU2003259475A1 (es) |
BR (1) | BR0314302A (es) |
CA (1) | CA2496295C (es) |
CO (1) | CO5550456A2 (es) |
DE (1) | DE60330362D1 (es) |
EA (1) | EA200500377A1 (es) |
EC (1) | ECSP055679A (es) |
ES (1) | ES2335099T3 (es) |
HR (1) | HRP20050247A2 (es) |
IS (1) | IS7698A (es) |
MA (1) | MA27440A1 (es) |
MX (1) | MXPA05002376A (es) |
NO (1) | NO20050838L (es) |
OA (1) | OA12929A (es) |
PA (1) | PA8583201A1 (es) |
PE (1) | PE20040988A1 (es) |
PL (1) | PL375979A1 (es) |
UY (1) | UY27985A1 (es) |
WO (1) | WO2004026306A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200500354A1 (ru) | 2002-09-18 | 2005-10-27 | Пфайзер Продактс Инк. | Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) |
DE60330362D1 (de) * | 2002-09-18 | 2010-01-14 | Pfizer Prod Inc | Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) |
ES2325687T3 (es) * | 2002-09-18 | 2009-09-14 | Pfizer Products Inc. | Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf). |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
WO2006026305A1 (en) * | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc | Pyrimidinylpyrazoles as tgf-beta inhibitors |
WO2006028029A1 (ja) * | 2004-09-07 | 2006-03-16 | Sankyo Company, Limited | 置換ビフェニル誘導体 |
JP2008516962A (ja) * | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
KR20080082618A (ko) * | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Alk5 조절제를 사용한 안압의 조절 |
GEP20115239B (en) | 2006-10-31 | 2011-06-10 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptor antagonists |
WO2009016460A2 (en) * | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
PL3089971T3 (pl) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
WO2016160881A1 (en) | 2015-04-01 | 2016-10-06 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
DK3470409T3 (da) * | 2016-06-13 | 2020-05-11 | Genfleet Therapeutics Shanghai Inc | Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer |
US11266647B2 (en) * | 2016-10-26 | 2022-03-08 | Icahn School Of Medicine At Mount Sinai | Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition |
WO2018086609A1 (zh) * | 2016-11-14 | 2018-05-17 | 江苏恒瑞医药股份有限公司 | 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用 |
WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CN111479809B (zh) * | 2017-12-13 | 2021-10-29 | 劲方医药科技(上海)有限公司 | 一种TGF-βRI抑制剂的晶型、盐型及其制备方法 |
US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
TW202012390A (zh) * | 2018-06-29 | 2020-04-01 | 日商日本歐愛特農業科技股份有限公司 | 新穎之經取代吡唑衍生物 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US10952996B2 (en) | 2018-12-11 | 2021-03-23 | Theravance Biopharma R&D Ip, Llc | ALK5 inhibitors |
CN110467601B (zh) * | 2019-08-29 | 2021-07-02 | 杭州市西溪医院 | 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用 |
TW202132297A (zh) | 2019-11-22 | 2021-09-01 | 美商施萬生物製藥研發Ip有限責任公司 | 經取代吡啶及使用方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (es) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4925857A (en) * | 1989-03-22 | 1990-05-15 | Sterling Drug Inc. | Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents |
JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
EP0983260A2 (en) | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
JP2002541253A (ja) | 1999-04-09 | 2002-12-03 | スミスクライン・ビーチャム・コーポレイション | トリアリールイミダゾール |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
WO2002040468A1 (en) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
EP1363904A1 (en) * | 2001-02-02 | 2003-11-26 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
JP2004521915A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Tgf過剰発現に対するピラゾール誘導体 |
MXPA03008142A (es) | 2001-03-09 | 2003-12-12 | Pfizer Prod Inc | Nuevos compuestos antiinflamatorios de bencimidazol. |
EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
US20050245520A1 (en) | 2002-07-31 | 2005-11-03 | Nerina Dodic | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors |
ES2325687T3 (es) | 2002-09-18 | 2009-09-14 | Pfizer Products Inc. | Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf). |
MXPA05002982A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Derivados de triazol como inhibidores del factor de crecimiento transformante (tgf). |
AP2005003262A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. |
EA200500354A1 (ru) | 2002-09-18 | 2005-10-27 | Пфайзер Продактс Инк. | Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) |
DE60330362D1 (de) | 2002-09-18 | 2010-01-14 | Pfizer Prod Inc | Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
-
2003
- 2003-09-08 DE DE60330362T patent/DE60330362D1/de not_active Expired - Lifetime
- 2003-09-08 AP AP2005003263A patent/AP2005003263A0/xx unknown
- 2003-09-08 BR BR0314302-3A patent/BR0314302A/pt not_active IP Right Cessation
- 2003-09-08 EA EA200500377A patent/EA200500377A1/ru unknown
- 2003-09-08 AU AU2003259475A patent/AU2003259475A1/en not_active Abandoned
- 2003-09-08 KR KR1020057004598A patent/KR20050044807A/ko not_active Application Discontinuation
- 2003-09-08 EP EP09177298A patent/EP2165708A3/en not_active Withdrawn
- 2003-09-08 MX MXPA05002376A patent/MXPA05002376A/es active IP Right Grant
- 2003-09-08 OA OA1200500078A patent/OA12929A/en unknown
- 2003-09-08 ES ES03797443T patent/ES2335099T3/es not_active Expired - Lifetime
- 2003-09-08 JP JP2004568904A patent/JP4519657B2/ja not_active Expired - Fee Related
- 2003-09-08 EP EP03797443A patent/EP1542684B1/en not_active Expired - Lifetime
- 2003-09-08 CA CA2496295A patent/CA2496295C/en not_active Expired - Fee Related
- 2003-09-08 CN CNA038222655A patent/CN1681501A/zh active Pending
- 2003-09-08 AT AT03797443T patent/ATE450258T1/de not_active IP Right Cessation
- 2003-09-08 WO PCT/IB2003/003933 patent/WO2004026306A2/en active Application Filing
- 2003-09-08 PL PL03375979A patent/PL375979A1/xx not_active Application Discontinuation
- 2003-09-15 PE PE2003000940A patent/PE20040988A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103356A patent/AR041272A1/es unknown
- 2003-09-16 UY UY27985A patent/UY27985A1/es not_active Application Discontinuation
- 2003-09-17 US US10/667,189 patent/US6958354B2/en not_active Expired - Fee Related
- 2003-09-17 PA PA20038583201A patent/PA8583201A1/es unknown
-
2005
- 2005-02-16 NO NO20050838A patent/NO20050838L/no unknown
- 2005-02-17 IS IS7698A patent/IS7698A/is unknown
- 2005-03-16 CO CO05024529A patent/CO5550456A2/es not_active Application Discontinuation
- 2005-03-16 HR HR20050247A patent/HRP20050247A2/hr not_active Application Discontinuation
- 2005-03-16 EC EC2005005679A patent/ECSP055679A/es unknown
- 2005-03-18 MA MA28154A patent/MA27440A1/fr unknown
- 2005-09-23 US US11/234,564 patent/US7151110B2/en not_active Expired - Fee Related
-
2006
- 2006-11-08 US US11/557,638 patent/US7638537B2/en not_active Expired - Fee Related
-
2009
- 2009-11-12 US US12/617,027 patent/US20100056571A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12929A (en) | Pyrazole derivatives as transforming growth (TGF) inhibitors. | |
EP1542990B1 (en) | Novel imidazole compounds as transforming growth factor (tgf) inhibitors | |
US7053095B2 (en) | Triazole compounds as transforming growth factor (TGF) inhibitors | |
US7030125B2 (en) | Isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors | |
EP1606267B1 (en) | Pyrazine compounds as transforming growth factor (tgf) inhibitors | |
ZA200502277B (en) | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |